Satoshi Kobayashi

21PUBLICATIONS
51CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer geneticsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Aug 28, 2026
Programmed death-ligand 1 expression in gastric cancer by the combined positive score using the PD-L1 IHC 28-8 pharmDx test: a single institution's experience.

|Aug 27, 2026
Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma in Early Real-World Clinical Practice: A Multicenter Analysis of Efficacy and Safety.

|Sep 25, 2025
Carbon-Ion Radiation Therapy Compared to Surgical Resection for Primary, Solitary, Potentially Resectable Hepatocellular Carcinoma.

Soichiro Morinaga, Shinnosuke Kawahara, Rei Kanemoto

|Sep 06, 2025
Combination chemotherapy for older patients with unresectable biliary tract cancer: a prospective observational study using propensity-score matched analysis (JON2104-B).

Satoshi Kobayashi, Kohei Nakachi, Kouji Yamamoto

|Jul 28, 2025
Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial.

Akihiro Ohba, Masato Ozaka, Junki Mizusawa

|Jun 30, 2025
Peritoneum carcinomatosis as a favourable prognostic factor for treatment with nanoliposomal irinotecan and fluorouracil plus leucovorin in advanced pancreatic cancer.

Satoshi Kobayashi, Taito Fukushima, Shun Tezuka

Pageof 4

Frequent Collaborators

5 joint publications

Masafumi Ikeda

4 joint publications

Naohiro Okano

3 joint publications

Junji Furuse

3 joint publications

Taito Fukushima